INSIGHTEC's Exablate Neuro approved for Parkinson’s disease patients

By Staff News Brief

Exablate Neuro, a magnetic resonance imaging (MRI)-guided focused ultrasound system from INSIGHTEC, has received an approval from the U.S. Food and Drug Administration (FDA) to be used to treat patients with tremor-dominant Parkinson’s disease. This expansion adds medication-refractory tremor from Parkinson’s disease to the current Exablate Neuro indication for incisionless, focused ultrasound thalamotomy for medication-refractory essential tremor.

 

The Haifa, Israel-headquartered company said that this expansion offers a treatment option in lieu of conventional cranial surgery for patients with medication-refractory tremor. Focused ultrasound is not curative for Parkinson’s disease, but has been shown in clinical trials to provide significant quality of life benefits.

Back To Top

INSIGHTEC's Exablate Neuro approved for Parkinson’s disease patients .  Appl Radiol. 

By Staff News Brief| January 07, 2019
Categories:  Section

About the Author

Staff News Brief

Staff News Brief



Copyright © Anderson Publishing 2019